The report covers forecast and analysis for the Uveitis Treatment market on a global and regional level. The study provides historic data from 2016 to 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes drivers and restraints for the Uveitis Treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Uveitis Treatment market on a global level. In order to give the users of this report a comprehensive view on the Uveitis Treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein treatment type, disease type, distribution channel, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.
Uveitis is the inflammation of the eye's middle layer called the uvea. It may emerge from causes that are both infectious and non-infectious. The uvea supplies the retina with blood. The retina is the light-sensitive part of the eye that focuses and sends the images to the brain. Because of its blood supply from the uvea, it is usually red. Uveitis is not usually severe. If not treated early, more severe cases may cause vision loss. In one or both eyes, the following symptoms may occur: severe redness in the eye, pain, dark floating spots in your vision, called floaters, light sensitivity and blurred vision. The cause of uveitis is often uncertain and often happens in people who are otherwise well. Sometimes it can be linked with another illness such as an autoimmune disorder or a virus or bacterial infection.
The study provides a decisive view on the Uveitis Treatment market by segmenting the market based on treatment type, disease type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2025. Based on product, the market is segmented into corticosteroids, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics. In 2018, corticosteroids dominated the market for anterior uveitis treatment as they are anterior uveitis first-line therapies. They are used as both eye drops and systematic therapy. Corticosteroids are also used in the treatment of continued release, i.e., in implants of the eye. Based on disease type, the market is segmented into anterior uveitis, posterior uveitis, intermediate uveitis and panuveitis. Anterior uveitis led the market space in 2018 due to the high prevalence of adult and youth condition. Increasing work in this field also illustrates the rising age of this type of disease. There is a high risk of loss of vision and cataract, glaucoma, or retinal edema for people with untreated anterior uveitis. Based on distribution channel, the market is segmented into hospitals, ophthalmology clinics, ambulatory surgical centers, and others. Due to the availability of a wide range of options for managing eye inflammation in hospitals, hospital pharmacies led the market in 2018 based on the distribution channel. In addition, hospitals provide a significant number of patients with treatment and care, making hospital pharmacies a leading category. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa with its further bifurcation into major countries such as US, Canada, Germany, UK, France, China, Japan, India, GCC countries, Brazil. Due to the rising prevalence of non-infectious uveitis in the United States, North America led the market in 2018. Additionally, advanced health care facilities and reimbursement policies are attributed to stimulate regional development. Large numbers of drugs are available commercially in the U.S., further boosting the country's demand.
New developments in drug formulations and treatment modalities are continuing, for instance, a major breakthrough was Humira's approval for uveitis care. As a consequence, some of the driving factors are projected to be factors such as rising geriatric population, increasing disease incidence, and new product innovations Redness of the eyes, blurring of the vision, small size of the pupil, and sensitivity to light may be signs of anterior uveitis that may result in permanent blindness if not treated. Increasing occurrence of optical infections coupled with increased knowledge of different treatments is likely to help growth of the market over the forecast period. Some other drivers of the industry are high spending on insurance, increased disposable income, and favorable government regulations.
Key players within global Uveitis Treatment market include Allergan, Inc.; Bausch & Lomb Incorporated; Santen Pharmaceutical Co., Ltd; AbbVie Inc.; Novartis AG; Eyegate Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Eyepoint pharmaceuticals Inc.; and Alimera Sciences, Inc. amongst others.
The report segments global Uveitis Treatment market as follows:
Global Uveitis Treatment Market: Treatment type Segment Analysis
Global Uveitis Treatment Market: Disease type Segment Analysis
Global Uveitis Treatment Market: Distribution Channel Segment Analysis
Global Uveitis Treatment Market: Regional Segment Analysis